Australian researchers have confirmed the protein involved in Gleevec’s transport into chronic myelogenousleukemia (CML) cells and have shown that it is the activity of this protein which is a key determinant of response in CML patients.
Robert G. Maki, M.D., Ph.D. talks about how molecular clues help refine Kinase Inhibitor strategy for GI. In the post-imatinib (Gleevec) era, treatment of gastrointestinal stromal tumors has shifted from serial surgeries to refinement of kinase [...]
Here is a video on Serum Imatinib (Gleevec) Levels Predict GIST Response. George D. Demetri, M.D., discusses how Gleevec levels predict GIST response. Higher circulating levels of imatinib (Gleevec) correlated with better clinical responses in patients with [...]
Thirteen GIST abstracts were presented this year at the 2008 Gastrointestinal Cancers Symposium, sponsored by the American Society of Clinical Oncology (ASCO). Space limitations will not permit us to report on all of these abstracts.
By Jim Hughes LRG Science Coordinator International AZD2171 Phase II: The AZD2171 Phase II Trial in the UK is now listed as "Not recruiting". Dasatinib Phase II: This new trial for GIST is now [...]